ABSTRACT
BACKGROUND Glioblastoma (GB) gold standard treatment combines maximally-safe surgical resection of the contrast-enhanced (CE) central tumor area, as defined by MRI, and chemo-radiotherapy. However, most patients relapse within one year in non-CE peritumoral FLAIR regions. Spectroscopy MRI (MRSI) can discriminate metabolic tumor areas with higher recurrence potential. We showed that regions with Choline/N-acetyl-aspartate index >2 (CNI+) were predictive of relapse sites post-radiotherapy in CE and FLAIR areas. As relapses are mainly imputed to a subpopulation of aggressive and resistant tumor stem-like cells, called GB-initiating cells (GIC), this suggests that CNI+ areas might be enriched in GIC.
METHODS We conducted a prospective trial in 16 eligible GB patients subjected to preoperative MRSI/MRI and subsequent surgery/chemo-radiotherapy to investigate GIC enrichment of CNI+ versus CNI− areas, based on biopsies in CE and FLAIR. We combined in vitro/vivo biological characterization of biopsies and derived GIC lines with biopsy RNAseq analyses.
RESULTS Biopsy characterization by FACS and RNAseq revealed that FLAIR/CNI+ areas showed an enrichment in GIC-population and in stem-related gene signature, but also in pathways related to DNA repair, adhesion/migration and mitochondrial bioenergetics. More, FLAIR/CNI+ samples gave rise to GIC-enriched neurospheres faster than CNI− counterparts. Finally, parameters assessing Biopsy GIC Content and Time to Neurosphere formation in FLAIR/CNI+ areas were associated with worse patient outcome.
CONCLUSION Preoperative MRI/MRSI combination would certainly allow better resection and targeting of CNI+ areas in FLAIR, as their GIC-enrichment can predict worse outcome in GB patients.
TRIAL REGISTRATION ClinicalTrials.gov NCT01872221.
FUNDING RITC (RECF1929), GRICR and Plan Cancer 2016 (HTE).
Competing Interest Statement
E Cohen-Jonathan Moyal served as board expert for Novocure and received research grants from Astra Zeneca, Novocure, Incyte and Bayer. T. Filleron served as a consultant for Cellectis and received honoraria from Roche and Lilly. The other authors have declared that no conflict of interest exists
Clinical Trial
NCT01872221
Funding Statement
RITC (RECF1929), GRICR and Plan Cancer 2016 (HTE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This trial was reviewed and approved by the institutional review board, the French ethics committee, on 30/05/2012 (registration number 2012-A00585-38) and the French Drug Administration (ANSM) on 15/06/2012 (registration number B120639-40).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest: E Cohen-Jonathan Moyal served as board expert for Novocure and received research grants from Astra Zeneca, Novocure, Incyte and Bayer. T. Filleron served as a consultant for Cellectis and received honoraria from Roche and Lilly. The other authors have declared that no conflict of interest exists.
Data Availability
All data produced in the present work are contained in the manuscript, with the exception of the raw RNAseq data, which will be publicly available upon acceptance for publication.